Inovio Pharmaceuticals, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (19)

View All

Latest Articles

About This Stock More About This Stock
Inovio Discloses Deal Break-up Over Prostate Cancer Deal - Roche To Still Collaborate On Hepatitis B Vaccine
Article By: Terry Chrisomalis
Monday, November 17, 2014 1:24 PM EDT
Inovio Pharmaceuticals Tumbles After Roche Deal Falls Apart On Prostate Cancer Vaccine Deal
In this article: JNJ, INO, RHHBY, MDVN
Read
Biotech Stocks: The Sector's Most Comprehensive Immunotherapy Platforms
Article By: BioMedReports
Friday, November 7, 2014 4:58 AM EDT
The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
In this article: INO, NWBO, TPIV, DNDN, GALE
Read
Ebola's Financial Implications (Updated)
Article By: Mary Hunt
Thursday, October 23, 2014 12:20 PM EDT
Even with human costs paramount, a global crisis has impact on investments.
In this article: AGN, BCS, GSK, JNJ, INO, BCRX, NLNK, TKMR, SRPT
Read
Inovio Pharmaceuticals: Partnerships Keep Rolling In
Article By: Terry Chrisomalis
Tuesday, October 21, 2014 1:32 PM EDT
Inovio Pharmaceuticals partners with MedImmune to create monoclonal antibodies against various infections.
In this article: AZN, INO, RHHBY
Read
Biotech Investors Gamble On Ebola Stocks
Article By: BioMedReports
Tuesday, October 7, 2014 6:39 AM EDT
The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA’s awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more than constant media attention.
In this article: HEB, INO, TPIV, TKMR
Read
“New Frontier Stocks” At Play In The Battle Against Ebola
Article By: M.E. Garza
Sunday, October 5, 2014 10:34 AM EDT
Several public companies have thrown their hats into the Ebola pandemic conversation, but only some will perform well for investors day in and day out.
In this article: HEB, INO, TPIV, TKMR
Read
All Posts

Latest Tweets for $INO

No tweets yet!

PARTNER HEADLINES